Neovasc Inc

Neovasc — Investor Presentation (February 2009)

32 slides from Neovasc's investor presentation, February 2009

  1. Slide 1: Neovasc Inc.

    Neovasc Inc. February 2009 Alexei Marko, CEO Chris Clark, CFO

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words “anticipates,” “believes,” “may,” “continues,” “estimates,” “expects,” and “will” and words of similar import, constitute “forward-loo

  3. Slide 3: Neovasc at-a-Glance

    Neovasc at-a-Glance • Medical device company specializing in vascular and tissue-based devices • Initial products approved in US/EU and generating early revenues – (target ~$2M in 2008, ~50% growth in 2009) • Strong product portfolio based on multiple technology platforms • Targeting large underserv

  4. Slide 4: Neovasc: Review

    Neovasc: Review July 2008 • Neovasc formed with acquisition of two Israeli medical device companies • Portfolio of vascular technologies, backed by strong investors, management and strategic advisors Strategy: • Aggressively commercialize portfolio of vascular products through internal development a

  5. Slide 5: Responding to Economic Downturn

    Responding to Economic Downturn October 2008 – Strategy adjustment • Cost rationalization – 40% reduction in headcount, including US sales force – Mothballed projects with revenue not realizable in next 12 months • Focus on near term revenues – Expand existing tissue business – Expand OEM/contract m

  6. Slide 6: Neovasc: Today

    Neovasc: Today February 2008 • $2.5m cash on hand at Jan 1, 2009 • Existing and growing revenues • Lean operations • Active involvement from key investors Revised Strategy: • Near term revenue growth (~50% in 2009/2010) • Drive for break even in late 2010 • Launch 3 new products by early 2010 • Rais

  7. Slide 7: Two Growth Platforms

    Two Growth Platforms Interventional Products Surgical Products Products for use during Products for use during open catheter-based treatment of or minimally invasive surgical vascular disease procedures

  8. Slide 8: Key Market Drivers

    Key Market Drivers • Aging population and better management of “routine” coronary vascular disease resulting in more: – Peripheral artery disease – End-stage heart disease – Complex vascular cases • Surgical trend towards tissue-based implantable vs. synthetic

  9. Slide 9: Interventional Products

    Interventional Products Metricath™ Arterial Measurement System Reducer™ Treatment for Refractory Angina Ostial Flare Vascular Balloon Catheter

  10. Slide 10: Metricath™

    Metricath™ Clinical Need: MD’s often have difficulty making precise measurements of arteries during angioplasties • Provides precise size measurements for: – selecting stent or treatment catheter size – ensuring complete stent expansion • Metricath Libra “measure only” – FDA-cleared and CE-marked •

  11. Slide 11: Reducer™

    Reducer™ Clinical Need: MD’s faced with critically ill angina patients for whom there is no effective treatment • Reducer treats refractory angina – chronic heart pain from inadequate blood flow to the heart muscle – ~2M patients in the US/EU and ~200k new patients/yr – drugs not providing pain reli

  12. Slide 12: Reducer™

    Reducer™ Patient with Angina Patient with Reducer Oxygenated blood feeds heart muscle through “coronary arteries” inflow Improved penetration of Poor blood flow oxygenated into heart muscle. blood to feed Severe angina pain. heart muscle. Reduced angina pain. outflow Reducer implanted to restrict ou

  13. Slide 13: Reducer™

    Reducer™ • Implanted using standard catheter-based techniques (15 min. procedure) • Compelling clinical data from first human trial - published in JACC: – 15 patients – No device-related adverse events or complications – Significant improvement in majority of subjects • 3 year follow up in progress

  14. Slide 14: Reducer™

    Reducer™ • Product completed and undergoing final validation and transfer to manufacture • Filing for EU approval (CE-Mark) in mid 2009 • US FDA approval process (PMA) will be initiated following CE-mark approval

  15. Slide 15: Ostial Flare

    Ostial Flare Clinical Need: Implanting stents at ostial locations is difficult, time consuming and prone to complications • Difficult to position a vascular stent properly at the origin of an artery where it branches from the aorta (“the ostium”). • Treat 200,000 ostial lesions/yr in US. Stent protr

  16. Slide 16: Ostial Flare

    Ostial Flare • “Ostial Flare” catheter used after stent implantation to expand and “flare” protruding section of stent 1. Implant desired stent at ostium 2. Use Neovasc catheter to “post-dilate” stent and shape any protruding section fit to the anatomy 3. First “flare” products into US/EU market in

  17. Slide 17: Surgical Products

    Surgical Products PeriPatch™ Implantable Surgical Tissue MatrixBP™ Remodelable Surgical Tissue Aegis™ Staple Line Buttress System

  18. Slide 18: PeriPatch™ Technology

    PeriPatch™ Technology • Specially treated bovine and equine pericardial tissue • Initially developed for implantable heart valve applications • Proprietary treatment process creates implantable, biocompatible collagen tissue that retains physical characteristics of natural tissue • Adapted for gener

  19. Slide 19: PeriPatch™ Products

    PeriPatch™ Products • Available in a variety of shapes and sizes • Significant advantages over synthetic materials Handles like natural tissue Exceptional tensile and suture retention strength Does not require special sutures Reduced suture line bleeding / leakage • Sell directly and through strateg

  20. Slide 20: Peripatch™ “Strips”

    Peripatch™ “Strips” Clinical Need: Carotid artery patch that handles like human tissue and is not prone to suture line leakage • Specially shaped strips used for vascular repair procedures • Primary target is “carotid endarterectomies” (180k cases/yr in US) • Distributed exclusively by LeMaitre Vasc

  21. Slide 21: Matrix BP

    MatrixBP TM Clinical Need: Implantable surgical patch that becomes incorporated into the body over time • Tissue “remodels” to become incorporated into host tissue • Ideal for surgical applications where only temporary reinforcement is needed • Under development, expect initial regulatory approvals

  22. Slide 22: Aegis™

    Aegis™ Clinical Need: Leakage around staple lines is a major source of serious surgical complications • Buttress of tissue under staples to minimize leakage of blood/fluid • Fits standard endoscopic staplers • Used primarily in minimally invasive thoracic and bariatric surgery • Initial products FDA

  23. Slide 23: Neovasc Contract Services

    Neovasc Contract Services • Supply Neovasc tissue to multiple endovascular valve companies & other device manufacturers for incorporation into their own products • Contract manufacturing services • Product development services

  24. Slide 24: Product Summary

    Product Summary Product Total Market Size Status Reducer $6b • Development substantially complete (stent for refractory angina) (2M cases @ $3,000) • Filing for CE Mark in 2009 Ostial Flare $100m • Under development (stent flaring catheter) (200K cases @ $500) • Filing for approvals mid 2009 Metrica

  25. Slide 25: Financial Forecasts: Revenue and Contribution

    Financial Forecasts Revenue and Contribution 4,000 3,000 2,000 1,000 $000s Revenue - Contribution FY8Q3 FY9Q1 FY9Q3 FY10Q1 FY10Q3 FY11Q1 FY11Q3 -1,000 -2,000 -3,000 -4,000 Quarter

  26. Slide 26: Financial Forecasts: Expenses

    Financial Forecasts Expenses 4,000 3,000 2,000 1,000 $000s - Expenses FY8Q3 FY9Q1 FY9Q3 FY10Q1 FY10Q3 FY11Q1 FY11Q3 -1,000 -2,000 -3,000 -4,000 Quarter

  27. Slide 27: Financial Forecasts: Break Even

    Financial Forecasts Break Even 4,000 3,000 2,000 1,000 Revenue $000s Contribution - Expenses FY8Q3 FY9Q1 FY9Q3 FY10Q1 FY10Q3 FY11Q1 FY11Q3 -1,000 EBITDA -2,000 -3,000 -4,000 Quarter

  28. Slide 28: Capitalization & Trading

    Capitalization & Trading • 17.7M (issued and outstanding) Shares outstanding • 22.9M (fully diluted) • TSX-V NVC Public listings • Application for US listing underway • Frost Group (Dr. Philip Frost) Key investors • Peregrine Ventures • Company management • 60% of shares held by management and insid

  29. Slide 29: 2009 Financing

    2009 Financing • $2.5m private placement • Initial commitments in place from senior management, BOD and SAB • Close in early Q2 • Use of Proceeds: – Expansion of tissue and contract business – Launch Reducer in EU – Launch Ostial Flare in US/EU – Launch remodellable tissue in US • Reach break even l

  30. Slide 30: Clinical Advisors

    Clinical Advisors Our Advisors include leading practitioners and opinion leaders Dr. David Allie Dr. Gary Ansel Dr. Shmuel Banai Dr. Rajesh Dave Dr. Arik Finkelstein Dr. Robert Bonow Dr. Jorge Saucedo Dr. Michael Jaff Dr. Elazar Edelman Dr. Robert Tahara Dr. Ken Rosenfeld Dr. Tim Henry Dr. Craig Wal

  31. Slide 31: Management and Board

    Management and Board Management Board of Directors Alexei Marko - CEO and board member Paul Geyer (former CEO, Mitroflow) Chris Clark - CFO Steven Rubin (Frost Group, OPKO) Cynthia Roney - VP Sales & Marketing Dr. Jane Hsiao (Frost Group, OPKO) Brian McPherson - VP Operations Boaz Lifschitz (Peregri

  32. Slide 32: Summary

    Summary Underserved & growing markets in vascular Market opportunity and surgical medicine Business model Multiple products to meet clear clinical needs Experienced management, directors & Leadership clinical advisors Cash on hand, controlled costs and growing Financial near term revenues Achieve po

Neovasc — Investor Presentation (February 2009) on 6ix